|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Corthera Inc.
| | | Phone: | (650) 622-1500 | Year Established: | 2003 | Main Contact: | Stan E. Abel, President & CEO | | Other Contacts: | Dennis Stewart, Ph.D., Principal Scientist & Founder Ernst Rinderknecht, Ph.D., VP, Process Science and Manufacturing Elaine Unemori, Ph.D., VP, Clinical Development Rick Orr, J.D., COO Sam Teichman, MD, FACC, FACP, CMO
| | Company Description | Corthera, (formerly BAS Medical), a Novartis company, is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera’s lead product candidate, relaxin, is currently being evaluated in a global, phase 2/3 clinical trial for acute decompensated heart failure. Corthera has worldwide rights to develop and commercialize relaxin.
On Feb 3, 2010, Novartis completed its acquisition of Corthera for $120 million. Novartis will gain exclusive worldwide rights to relaxin, a recombinant version of a naturally occurring human peptide, through the acquisition of the privately held US biopharmaceutical company Corthera Inc. Relaxin is currently in Phase III clinical trials as a potential treatment option for patients with acute decompensated heart failure (ADHF).
Novartis will assume full responsibility for the development and commercialization of relaxin, with regulatory submissions in the US and Europe planned for 2013. The US Food and Drug Administration (FDA) has granted "Fast Track¨ designation to relaxin as part of its program to expedite the review of new drugs intended to treat serious or life-threatening conditions that can potentially address unmet medical needs. | |
|
|
|
|
|